This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q66073065
rdf:type
wikibase:Item
schema:description
clinical trial ensayu clínicu клінічне випробування klinisch onderzoek
rdfs:label
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder
skos:prefLabel
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder
schema:name
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder
p:P1476
wds:Q66073065-EACAE5EF-8DFA-43D2-AE28-BEB3C859667C
wdt:P1476
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With REL-1017 25 mg Daily and 50 mg Daily as Adjunctive Therapy in the Treatment of Patients Diagnosed With Major Depressive Disorder
p:P582
wds:Q66073065-7BA6377E-ADBE-4CAF-B662-7EA14E332FF3
wdt:P582
2019-05-01T00:00:00Z
p:P31
wds:Q66073065-4FBB0C05-E470-4E0B-B311-C5C14D11C3EE
wdt:P31
wd:Q30612
p:P580
wds:Q66073065-F4D2A98A-C21E-41B0-8B70-A1018360908A
wdt:P580
2018-05-11T00:00:00Z
p:P17
wds:Q66073065-E5111A44-4A9F-4BE6-9935-AC1D08662F7B
wdt:P17
wd:Q30
p:P6153
wds:Q66073065-C8F0EB43-181A-41EE-9CD4-CB5A4FF3FC27 wds:Q66073065-3BEB2D43-A1E3-4D53-9F16-5DF79512C4D6
wdt:P6153
wd:Q30269674 wd:Q30269522
p:P2899
wds:Q66073065-1403958C-9E7B-4114-8EEF-5285B8B06FC7
wdt:P2899
18
p:P1132
wds:Q66073065-A99EA2E1-0297-49CF-B8B5-C43E8D6B8D9F
wdt:P1132
60
p:P4135
wds:Q66073065-6B927B9E-119E-4C5F-87D9-049A891255D2
wdt:P4135
65
p:P8363
wds:Q66073065-DAAC394C-485D-427B-9A78-55BEEFD7F9E9
wdt:P8363
wd:Q78089383
p:P3098
wds:Q66073065-081A428B-84FC-4566-8D5C-9B445900B7C2
wdt:P3098
NCT03051256
p:P6099
wds:Q66073065-2A018DA5-C2A1-45E4-B559-C8F8D5AD77DD
wdt:P6099
wd:Q42824440